Welcome to our dedicated page for Bristol-Myers Squibb Co SEC filings (Ticker: BMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bristol-Myers Squibb鈥檚 drug pipeline shifts with every FDA ruling and patent challenge, making its regulatory paperwork a critical read for anyone tracking biopharma risk and opportunity. Yet a single 10-K can exceed 250 pages of trial data, manufacturing details, and litigation notes.
Stock Titan brings these documents to life. Our platform delivers AI-powered summaries that turn dense R&D jargon into plain English, flags revenue swings drug by drug, and highlights patent-expiry timelines鈥攁ll in real time as each filing hits EDGAR. Whether you need the latest Bristol-Myers Squibb quarterly earnings report 10-Q filing or want to scan an Bristol-Myers Squibb 8-K material events explained, everything is one click away.
Use cases professionals rely on:
- Instant alerts for Bristol-Myers Squibb insider trading Form 4 transactions to gauge executive confidence.
- Side-by-side revenue trend charts pulled from every 10-Q so you can compare Opdivo and Eliquis growth without manual spreadsheet work.
- Concise red-flag notes inside the Bristol-Myers Squibb annual report 10-K simplified section鈥攑erfect for spotting looming patent cliffs.
- Full text search across the latest Bristol-Myers Squibb proxy statement executive compensation to understand incentive alignment.
Need real-time data? Our feed posts Bristol-Myers Squibb Form 4 insider transactions real-time within seconds of SEC acceptance. Curious about pipeline catalysts? Our AI tags every clinical update inside an 8-K so you never miss a material event. In short, this page is the fastest route to understanding Bristol-Myers Squibb SEC documents with AI and provides the deep Bristol-Myers Squibb earnings report filing analysis analysts demand.
Form 8-K, Item 7.01 鈥� Regulation FD. On 31 Jul 2025 Silexion Therapeutics Corp (SLXN) furnished a press release titled 鈥淪ilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation.鈥� The release describes laboratory findings that achieved up to 97 % inhibition of cancer-cell proliferation and activity against a novel KRAS mutation.
The disclosure is expressly 鈥渇urnished鈥� rather than 鈥渇iled,鈥� shielding it from Exchange Act 搂18 liability and preventing automatic incorporation into Securities Act filings. No financial metrics, clinical-trial results, regulatory milestones, or transactional details accompanied the announcement. Exhibit 99.1 contains the press release; Exhibit 104 is the Inline XBRL cover page. Ordinary shares (SLXN) and high-strike warrants (SLXNW) remain listed on Nasdaq.
Investor takeaway: Encouraging preclinical signal but very early in the development cycle; there is no immediate effect on revenue, guidance, or balance-sheet items.
Bristol-Myers Squibb (BMY) filed an 8-K on 31-Jul-2025 to furnish, rather than file, its second-quarter 2025 earnings materials.
- Item 2.02: Exhibit 99.1 is the press release containing Q2-25 results.
- Item 7.01: Exhibit 99.2 is an investor presentation used for the 8:00 a.m. ET conference call.
- Both exhibits include non-GAAP figures with GAAP reconciliations; no financial metrics appear in the body of the 8-K itself.
- The furnished status limits Exchange Act 搂18 liability and prevents automatic incorporation into future filings unless specifically referenced.
- No other material transactions, governance changes or financing actions were disclosed.
The filing also lists NYSE-traded securities鈥攃ommon stock, 1.750 % notes due 2035, and Celgene CVRs鈥攁nd contains standard emerging-growth-company and Regulation FD boilerplate.
Form 8-K 鈥� Item 5.02 (Departure of Certain Officers)
On 25 July 2025, Bristol-Myers Squibb Company (NYSE: BMY) reported that Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer & Head of Development, will step down from these roles effective 1 August 2025 and will fully exit the company on or before 1 November 2025. During the interim period he will act as an advisor.
Separation terms
- Cash severance governed by the U.S. Severance Benefits Plan.
- Pro-rated vesting of outstanding Market Share Units and Performance Share Units under the 2021 Stock Award & Incentive Plan.
- Prorated 2025 annual incentive under the Senior Executive Performance Incentive Plan.
No successor, strategic changes, or financial impact projections were disclosed. A related press release is furnished as Exhibit 99.1.
AutoZone, Inc. (AZO) Form 4 filing discloses that Vice President & Controller J. Scott Murphy purchased additional company stock on 30 June 2025.
- Shares acquired: 4 shares at $3,712.23 per share and an additional 1 share at $0.00 (likely plan-related rounding), for a total of 5 shares.
- Total cost: approximately $14,849 for the market-priced shares.
- Post-transaction holdings: 1,243.6799 shares held directly.
- Plan source: Acquisition made under the company鈥檚 Sixth Amended & Restated Executive Stock Purchase Plan.
The filing represents a routine insider purchase that modestly increases the officer鈥檚 ownership stake. While insider buying can signal confidence, the fractional size relative to AutoZone鈥檚 ~18 million outstanding shares renders the transaction immaterial to the broader investment thesis.
On 07/01/2025, General Counsel Victor S. Sze filed a Form 4 reporting the purchase of 75 shares of OSI Systems, Inc. (OSIS) common stock on 06/30/2025 at $140.61 per share through the company鈥檚 Employee Stock Purchase Plan. The transaction lifted his direct holdings to 78,353 shares, while indirect holdings held via the Sze Trust remain at 5,639 shares. No derivative securities activity or share sales were disclosed. With a total value of roughly $10,550, the trade is modest relative to Mr. Sze鈥檚 existing position and OSIS鈥檚 daily trading volume, suggesting a routine, non-material acquisition rather than a strategic signal.
Form 4 overview 鈥� ONE Group Hospitality, Inc. (STKS)
On 06/27/2025, 10% owner David Kanen and related entities (Kanen Wealth Management LLC, Philotimo Fund LP, and Philotimo Focused Growth & Income Fund) filed a joint Form 4 reporting a single open-market sale of 24,431 Class A common shares at $4.61 per share, generating roughly $113,000 in proceeds.
Post-transaction, the group reports the following indirect and direct holdings:
- Kanen Wealth Management LLC (KWM): 2,289,867 shares
- David Kanen (direct): 20,237 shares
- Philotimo Focused Growth & Income Fund: 393,975 shares
- Philotimo Fund, LP: 1,970,000 shares
Total disclosed beneficial ownership across all reporting persons equals approximately 4.67 million shares, sustaining their >10% ownership status.
Key footnote insight: KWM鈥檚 reported share count declined because several managed accounts are no longer considered beneficially owned after account-holder deaths and other uncontrollable events. Aside from the 24,431-share sale, the change in reported ownership is administrative rather than transactional.
Investor takeaway: The disposal represents < ~0.5%> of the group鈥檚 aggregate position and does not materially alter their strategic stake. However, it signals modest insider selling and clarifies why prior filings showed higher share totals.
Form 4 Overview 鈥� Carvana Co. (CVNA)
Chief Executive Officer and 10% owner Ernest C. Garcia III reported a series of open-market sales of Class A common stock executed on 27 June 2025 and 30 June 2025 under a Rule 10b5-1 trading plan adopted on 13 December 2024.
- Total shares sold: 19,580 (across two family trusts)
- Price range: $306.84 鈥� $334.63 per share; volume-weighted averages disclosed for each trade block
- Estimated proceeds: roughly $6 million (weighted average 鈮� $320/share)
- Residual ownership: 鈥� Direct: 925,613 shares
鈥� Indirect (Ernest Irrevocable 2004 Trust III): 701,650 shares
鈥� Indirect (Ernest C. Garcia III Multi-Generational Trust III): 801,650 shares
鈥� Total continuing beneficial ownership: 鈮� 2.43 million shares
The reported transactions represent <~1% of Garcia鈥檚 post-transaction holdings and are spread over two trading days, limiting immediate market impact. Because the sales were pre-scheduled under a 10b5-1 plan, they are generally viewed as routine liquidity events rather than a discretionary reduction in exposure.
No derivative securities were involved, and there were no purchases or option exercises disclosed.
Iron Mountain Inc. (IRM) has filed a Form 144/A signaling the possible sale of 17,334 common shares鈥攁bout 0.006 % of the company鈥檚 295,043,896 shares outstanding. The shares, acquired on 03/01/2025 via restricted-stock vesting (compensation), are valued at roughly $1.73 million and are expected to be sold on or after 07/01/2025 through Fidelity Brokerage Services LLC on the NYSE. No other sales were reported in the past three months, and the filer attests to holding no undisclosed material information. Although Form 144 filings can indicate insider intent to sell, the transaction size is immaterial relative to Iron Mountain鈥檚 float and therefore unlikely to affect the stock鈥檚 supply-demand dynamics.
On 1 July 2025, Oxford Industries, Inc. (ticker: OXM) filed a Form 4 disclosing that non-employee director Dennis M. Love received an equity grant on 30 June 2025.
- Type of security: 6,086 restricted common shares issued under the company鈥檚 Long-Term Stock Incentive Plan as part of Mr. Love鈥檚 annual director retainer.
- Transaction code: 鈥淎鈥� (acquisition) at a stated price of $0, indicating a grant rather than an open-market purchase.
- Post-transaction ownership: Mr. Love now directly holds 22,628 common shares.
No derivative securities were involved and no additional transactions were reported. The filing reflects routine director compensation and results in minimal dilution to existing shareholders.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
What is the primary business of Bristol-Myers Squibb?
Which therapeutic areas does the company specialize in?
How does Bristol-Myers Squibb generate its revenue?
What is the significance of its research and development efforts?
How does the company maintain its competitive edge in the market?
What role do collaborations and licensing agreements play in its strategy?
